*Read Disclaimer Sponsored Content
{{current_date_full}} | Unsubscribe
Hello!
New Alert: Immix Biopharma, Inc. (NASDAQ: IMMX)
IMMX is our brand new NASDAQ alert.
In October, IMMX rallied +102% from 2.00 to a high of 4.05.
Since this rally, IMMX has been consolidating above its 20 day moving average of 3.20.
This is a typical move after such a massive rally.
If it can hold above this level then it could be positioning for another rally higher.
IMMX is the “global leader in relapsed/refractory AL Amyloidosis”.
Each of our bodies has an immune system that recognizes and eliminates disease on a daily basis.
When AL Amyloidosis emerges from our own body, however, the diseased cells are able to evade the immune system.
“AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death.”
Sadly, “only one 4-drug combination exists for newly diagnosed patients only”.
However, “once relapse hits, there's nothing FDA approved”.
“Doctors often resort to reusing older drugs, despite their limited efficacy.”
IMMX found a breakthrough to change that hopeless sentence.
The company’s mission is simple – “Create medicines that work without destroying the patient.”
IMMX re-engineers the immune system to fight again.
IMMX’s “lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that filters out non-specific activation.”
“NXC-201 CAR-T therapy, or chimeric antigen receptor T-cell therapy, is a type of immunotherapy that uses the patient’s own immune cells, modified with ImmixBio proprietary technology, to create NXC-201, which is then introduced into the patient’s body.”
“Then the patient’s modified NXC-201 CAR-T cells are able to recognize and eliminate diseased cells, with up to a 92% rate of disease reduction (overall response rate) in the case of relapsed/refractory AL Amyloidosis.”
In other words:
“NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains.”
Despite impressive research and development progress in CAR-T cell therapies, “today 95% of U.S. medical centers are unable to dose CAR-T cell therapies due to neurotoxicity, and only a narrow band of patients in specific indications are able to benefit from CAR-Ts”.
IMMX is “aiming to become the first company to overcome the greatest obstacle to CAR-T adoption: neurotoxicity”.
By overcoming neurotoxicity, IMMX aims to “expand into select other serious diseases that were not possible in the past (starting with AL Amyloidosis), and places not possible in the past (the 95% of U.S. medical centers today that are unable to dose CAR-T therapies)”.
“NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design.”
Importantly:
“NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.”
Unfortunately, the “number of patients in the U.S. with relapsed/refractory AL Amyloidosis is estimated to be growing at 12% per year according to Staron, et al Blood Cancer Journal, to approximately 37,270 patients in 2025”.
The Amyloidosis market was “$3.6 billion in 2017, and is expected to reach $6 billion in 2025, according to Grand View Research”.
IMMX has announced multiple accomplishments over the past few months.
In August, the company announced:
“Immix Biopharma Announces Other Serious Diseases Strategy”
Here are the comments from this press release:
“While we are singularly focused on completing NEXICART-2 in relapsed/refractory AL Amyloidosis for BLA submission, promising NXC-201 clinical results could offer extraordinary one-and-done solutions in a number of other serious diseases. We plan to explore licensing-out these OSD programs through external partnerships,” said Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, "We believe partnerships could fuel our path to NEXICART-2 BLA submission for FDA approval and future development programs.”
In addition, in September, the company announced:
“Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang”
Here are some of the comments from this press release:
“Immix’s mission of curing the incurable resonates with Goose’s goal of investing in breakthrough technologies and innovative founders to forge the future of human medicine,” said Anthony George, President of Goose Capital. Ashok Rao, Board Member of Goose Capital, added, “After a deep evaluation of the technology, team, and market that Immix is pursuing, we are pleased to support, and anticipate exciting progress to-come.”
“We are thrilled that Dr. Chang and Goose recognize the opportunity for commercialization of NXC-201 in relapsed/refractory AL Amyloidosis, other serious diseases, and beyond,” said Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, “Goose and Dr. Chang bring unparalleled experience to the Immix team. Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, further enabling our goal to deliver widely accessible cures, as patients are waiting.”
As the company further noted in:
“Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors”
“At Tanox, Dr. Chang and her team invented and developed FDA-approved XOLAIR® (omalizumab) for severe asthma, TROGARZO® (ibalizumab-uiyk) for HIV, and EBGLYSS® (lebrikizumab-lbkz) for dermatitis, collectively generating drug sales exceeding 5 billion dollars so far.”
Plus:
“Tanox, Inc. was acquired by Genentech/Roche for $919 million.”
“EBGLYSS® is commercialized by Eli Lilly and Co.”
In addition, in September, the company announced:
“Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2”
Here are some of the company’s comments from this press release:
“With excitement generated by our clinical results presented at ASCO, surpassing 50% enrollment in NEXICART-2 demonstrates the growing interest among relapsed/refractory AL Amyloidosis clinicians and patients, where no drugs are FDA approved today,” said Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, “Growing excitement accelerates NEXICART-2 BLA submission for FDA approval, and supports future commercial awareness.”
In addition, IMMX will be participating at multiple conferences over the coming weeks:
“Immix Biopharma to Present at the Stifel 2025 Healthcare Conference”
“announced that it will present and host institutional investor meetings at the Stifel 2025 Healthcare Conference being held on November 11-13, 2025 at the Lotte New York Palace Hotel in New York, NY.”
“Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference”
“announced that it will present and host institutional investor meetings at the 37th Annual Piper Sandler Healthcare Conference being held on December 2-4, 2025 at the Lotte New York Palace Hotel in New York, NY.”
“Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting”
“announced that it will present a NXC-201 abstract at the upcoming American Society of Hematology (ASH) 67th Annual Meeting and Exposition to be held December 6-9, 2025, in Orlando, Florida.”
“Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference”
“announced that it will present and host institutional investor meetings at the Guggenheim 2nd Annual Healthcare Innovation Conference being held November 10-12, 2025 in Boston, MA.”
“Management will participate in a Fireside Chat on Tuesday, November 11, 2025 at 12:30pm Eastern Time.”
“Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025”
“announced that Phase 1/2 interim results from its U.S. NXC-201 NEXICART-2 trial in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming American Society of Hematology 2025 Annual Meeting (ASH 2025) being held in Orlando, Florida, December 6–9, 2025.”
IMMX could be positioned for another breakout opportunity.
Make sure to do your own due diligence.
Happy Trading!
SmallCapStocks Team
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
DISCLAIMER:
You should read and understand this disclaimer in its entirety before joining the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
Owners and operators of the Publisher have been compensated eight thousand five hundred dollars by bank wire transfer on 11/4/25 for the distribution of this advertisement about IMMX dated 11/5/25. Prior to the past year, at the time of publication, we disclosed our compensation for the distribution of advertisements about IMMX. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.
You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at [email protected] to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link:
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.